[go: up one dir, main page]

PA8508101A1 - Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. - Google Patents

Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.

Info

Publication number
PA8508101A1
PA8508101A1 PA20008508101A PA8508101A PA8508101A1 PA 8508101 A1 PA8508101 A1 PA 8508101A1 PA 20008508101 A PA20008508101 A PA 20008508101A PA 8508101 A PA8508101 A PA 8508101A PA 8508101 A1 PA8508101 A1 PA 8508101A1
Authority
PA
Panama
Prior art keywords
compound
syntheize
separation
target compound
useful
Prior art date
Application number
PA20008508101A
Other languages
English (en)
Inventor
Yang Bingwei Vera
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8508101A1 publication Critical patent/PA8508101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE AL COMPUESTO (+)-6-[AMINO-(6-CLORO-PIRIDIN-3IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-4(3-CLORO-FENIL)-1-CICLOPROPILMETIL-1H-QUINOLEIN-2-ONA,SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES DEL MISMO, Y PROFARMACOS DEL MISMO, Y AL USO DE DICHO COMPUESTO PARA INHIBIR UN DESARROLLO CELULAR ANORMAL, INCLUYENDO EL CANCER, EN ANIMALES MAMIFEROS. EL INVENTO SE REFIERE TAMBIEN A METODOS UTILES PARA SINTETIZAR EL SUSODICHO COMPUESTO.
PA20008508101A 2000-01-21 2000-12-04 Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. PA8508101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17771800P 2000-01-21 2000-01-21

Publications (1)

Publication Number Publication Date
PA8508101A1 true PA8508101A1 (es) 2002-08-26

Family

ID=22649709

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008508101A PA8508101A1 (es) 2000-01-21 2000-12-04 Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.

Country Status (17)

Country Link
US (1) US6479513B2 (es)
EP (1) EP1248782A1 (es)
JP (2) JP2003520796A (es)
AR (1) AR029792A1 (es)
AU (1) AU2001214087A1 (es)
BR (1) BR0016986A (es)
CA (1) CA2398353C (es)
CO (1) CO5271702A1 (es)
GT (1) GT200100008A (es)
HN (1) HN2000000266A (es)
MX (1) MXPA02007153A (es)
MY (1) MY126069A (es)
PA (1) PA8508101A1 (es)
PE (1) PE20011118A1 (es)
SV (1) SV2002000291A (es)
TN (1) TNSN01009A1 (es)
WO (1) WO2001053289A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
EP1347966B1 (en) 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en) 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
BR0317548A (pt) * 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105784A1 (en) * 2004-05-03 2005-11-10 Janssen Pharmaceutica N.V. Diastereoselective synthesis process for the preparation of imidazole compounds
DE602005007604D1 (de) 2004-05-03 2008-07-31 Janssen Pharmaceutica Nv Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine
US7572916B2 (en) 2004-05-03 2009-08-11 Janssen Pharmaceutica Nv Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
ATE533057T1 (de) 2005-09-20 2011-11-15 Osi Pharm Inc Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
US20070213366A1 (en) 2005-12-23 2007-09-13 Justman Craig J Treatment of Synucleinopathies
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2056874B1 (en) 2006-08-21 2012-09-19 F. Hoffmann-La Roche AG Tumor therapy with an anti-vegf antibody
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
JP6877429B2 (ja) 2015-12-03 2021-05-26 アジオス ファーマシューティカルズ， インコーポレイテッド Ｍｔａｐヌル癌を処置するためのｍａｔ２ａ阻害剤
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
ATE321757T1 (de) * 1995-12-08 2006-04-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren
JP3495706B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
BR0008202A (pt) * 1999-02-11 2002-02-19 Pfizer Prod Inc Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.

Also Published As

Publication number Publication date
AR029792A1 (es) 2003-07-16
PE20011118A1 (es) 2001-11-06
EP1248782A1 (en) 2002-10-16
US20020004514A1 (en) 2002-01-10
CA2398353C (en) 2007-07-31
JP2007326868A (ja) 2007-12-20
MXPA02007153A (es) 2002-12-13
WO2001053289A1 (en) 2001-07-26
US6479513B2 (en) 2002-11-12
SV2002000291A (es) 2002-07-16
TNSN01009A1 (fr) 2005-11-10
JP2003520796A (ja) 2003-07-08
MY126069A (en) 2006-09-29
HN2000000266A (es) 2001-05-21
CA2398353A1 (en) 2001-07-26
BR0016986A (pt) 2002-10-08
GT200100008A (es) 2001-10-19
CO5271702A1 (es) 2003-04-30
AU2001214087A1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
PA8508101A1 (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ECSP034600A (es) Compuestos de lactama
WO2008001101A3 (en) Pharmaceutical combinations
ECSP055807A (es) Quinolinilpirrolopirazoles
WO2005047898A3 (en) Methods and compositions for identifying therapeutic compounds
ES2134051T3 (es) Procedimiento para la preparacion de sildenafil.
CR20140215A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
PT1633697E (pt) Processo para a produção de compostos substituídos de 3-arilbutilamina
ATE433988T1 (de) Phosphoramidatderivate
ECSP045274A (es) N-aminoacetil-pirrolidina-2-carbonitrilosy su uso como inhibidores ddp-iv
WO2004098494A3 (en) Compounds, compositions, and methods
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
UY28856A1 (es) Nuevos imidazoles
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
BR0303666A (pt) Produção de quitosana
WO2004011449A3 (de) Verfahren zur herstellung von phenylalanin-derivaten
AU2003294837A1 (en) Improved method for the production of vitamin b12
WO2005021733A3 (en) Methods and compositions for sirna expression
EA200400876A1 (ru) Способ получения производных толуола
TW200621756A (en) Method for manufacturing enantiomeric imidazole compounds
AU2002231822A1 (en) Distributed database for one search key